98/393/EC: Commission Decision of 19 May 1998 on financial assistance from the Community for storage in France, Italy and the United Kingdom of antigen for production of foot-and-mouth disease vaccine (notified under document number C(1998) 1365) (Only the English, French and Italian texts are authentic) (Text with EEA relevance)
20. 6. 98 ‹ EN ‹ Official Journal of the European Communities L 176/25 II (Acts whose publication is not obligatory) COMMISSION COMMISSION DECISION of 19 May 1998 on financial assistance from the Community for storage in France, Italy and the United Kingdom of antigen for production of foot-and-mouth disease vaccine (notified under document number C(1998) 1365) (Only the English, French and Italian texts are authentic) (Text with EEA relevance) (98/393/EC) THE COMMISSION OF THE EUROPEAN COMMUNITIES, Having regard to the Treaty establishing the European Community, Having regard to Council Decision 90/424/EEC of 26 June 1990 on expenditure in the veterinary field (1), as last amended by Decision 94/370/EC (2), and in particular Article 14 thereof, Whereas by virtue of Council Decision 91/666/EEC of 11 December 1991 establishing Community reserves of foot- and-mouth disease vaccines (3), establishment of antigen banks the Community’s action to create Community reserves of foot-and-mouth disease vaccine; is part of Whereas the functions and duties of these antigen banks that Decision; whereas are specified in Article 4 of Community assistance must be conditional on accom- plishment of these; Whereas Community financial assistance should be granted to these banks to enable them to carry out during 1998 the said functions and duties; Whereas for budgetary reasons the Community assistance should be granted for a period of one year; Whereas for supervisory purposes Articles 8 and 9 of Council Regulation (EEC) No 729/70 of 21 April 1970 on financing of the common agricultural policy (4), as last amended by Regulation (EC) No 1287/95 (5), should apply; Whereas the measures provided for in this Decision are in accordance with the opinion of the Standing Veterinary Committee, Whereas Article 3 of that Decision designates the ‘Labora- toire de pathologie bovine du Centre national d’études vétérinaires et alimentaires’ at Lyon in France, the ‘Istituto Zooprofilattico Sperimentale die Brescia’ in Italy and the ‘Institute for Animal Health’ at Pirbright in the United Kingdom as antigen banks holding Community reserves; HAS ADOPTED THIS DECISION: Article 1 1. The Community shall grant France financial assis- tance for the stocking of antigen for production of foot- and-mouth disease vaccine. (1) OJ L 224, 18. 8. 1990, p. 19. (2) OJ L 168, 2. 7. 1994, p. 31. (3) OJ L 368, 31. 12. 1991, p. 21. (4) OJ L 94, 28. 4. 1970, p. 13. (5) OJ L 125, 8. 6. 1995, p. 1. L 176/26 ‹ EN ‹ Official Journal of the European Communities 20. 6. 98 2. The ‘Laboratoire de pathologie bovine du Centre national d’études vétérinaires et alimentaires’ at Lyon in France shall hold the stock of antigen to which paragraph 1 relates. The provisions of Article 4 of Decision 91/666/EEC shall apply. 3. The Community’s financial assistance shall be a maximum of ECU 40 000 for the period 1 January to 31 December 1998. — 70 % by way of an advance at the request of the Member State concerned, — the balance following presentation, by the Member supporting documents which State concerned, of demonstrate the effective completion of the tasks. 2. The supporting documents referred to in paragraph 1 must be presented to the Commission before 1 March 1999 and they should include: Article 2 (a) technical information on: 1. The Community shall grant Italy financial assistance for the stocking of antigen for production of foot-and- mouth disease vaccine. 2. The ‘Istituto Zooprofilattico Sperimentale di Brescia’ in Italy shall hold the stock of antigen to which para- graph 1 relates. The provisions of Article 4 of Decision 91/666/EEC shall apply. 3. The Community’s financial assistance shall be a maximum of ECU 40 000 for the period 1 January to 31 December 1998. Article 3 1. The Community shall grant the United Kingdom financial assistance for the stocking of antigen for produc- tion of foot-and-mouth disease vaccine. 2. The Institute for Animal Health at Pirbright in the United Kingdom shall hold the stock of antigen to which paragraph 1 relates. The provisions of Article 4 of De- cision 91/666/EEC shall apply. 3. The Community’s financial assistance shall be a maximum of ECU 40 000 for the period 1 January to 31 December 1998. Article 4 1. The Community’s financial assistance referred to in Article 1(3), Article 2(3) and Article 3(3) shall be paid as follows: — the amount and type of antigen stored (storage records), — storage equipment used (type, number and cap- acity of tanks), — security system in place (temperature control, anti-theft measures), — insurance arrangements (fire, accidents); (b) financial information (completion of table as shown in the Annex). Article 5 Articles 8 and 9 of Regulation (EEC) No 729/70 shall apply mutatis mutandis. Article 6 This Decision is addressed to the French Republic, the Italian Republic and the United Kingdom of Great Britain and Northern Ireland. Done at Brussels, 19 May 1998. For the Commission Franz FISCHLER Member of the Commission 20. 6. 98 ‹ EN ‹ Official Journal of the European Communities L 176/27 ANNEX Financial information related to the storage of antigen for production of foot-and-mouth disease vaccine STATEMENT OF COSTS Reporting period from. to. Reference No of Commission Decision providing financial assistance:. Name and address of beneficiary:. Category of costs Amount for the period (National currency) (1) 1. Staff 2. Capital equipment 3. Consumables 4. Insurance 5. Rental of premises (1) All costs must be expressed in national currency. Total Certificate by the beneficiary We certify that: — the above costs were incurred in connection with the tasks defined in the Decision and were essential to the sound performance of those tasks, — they are genuine costs falling within the definition of reimbursable costs, — all the documents supporting the costs are available for audit purposes. Date:. Name of technical director:. Signature:. Date:. Person financially responsible:. Signature: